Day Three arrives and Reuters Pharma 2023 comes to a close – but not before Boehringer Ingelheim talks to us about accelerating time-to-patient and an expert panel discusses empowering a wh
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho